What is your approach to biologic selection in a patient with resistant/persistent ABPA?   

Omalizumab has been shown to be helpful in reducing OCS use/exacerbations in refractory ABPA despite OCS and voriconazole. There are several case reports and reviews of patients who have been on anti-IL5s which have led to a reduction in eosinophilia but not necessarily exacerbations. There are seve...